

Please amend claims 12-14, 51-53, 57, 58, 60, 63, and 65 as shown:

1-7 (canceled).

8. (previously presented) The stent of claim 46 comprising:
a radially self-expanding tubular shaped member having first and second ends; a walled surface disposed between said first and second ends;
said walled surface comprising a plurality of substantially parallel pairs of monofilaments; said substantially parallel pairs of monofilaments woven in a helical shape such that substantially one-half of said substantially parallel pairs of monofilaments are wound clockwise in the longitudinal direction and one-half of said substantially parallel pairs of monofilaments are wound counterclockwise in the longitudinal direction such that an alternating, over-under plait of said substantially parallel pairs of monofilaments results; said monofilaments comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

9. (previously presented) The stent of claim 8, comprising approximately twenty-four substantially parallel pairs of monofilaments.

10. (previously presented) The stent of claim 8, wherein said bioresorbable, bio-compatible homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

11. (previously presented) The stent of claim 8, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

12. (currently amended) The stent of claim 8, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi ~~and~~ to 2,000,000 psi.

13. (currently amended) The bioresorbable stent of claim 8, wherein said stent has a compressed first diameter of between approximately 6 mm ~~to~~ and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

14. (currently amended) The bioresorbable stent of claim 8 wherein said woven monofilaments have a crossing angle of between approximately 100 degrees ~~to~~ and 150 degrees in the non-compressed resting state.

15-45 (canceled).

46. (previously presented) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising a blend of at least two bioresorbable, bio-compatible homopolymers, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.

47. (previously presented) The stent of claim 46 comprising:
a tubular-shaped member having first and second ends;
a walled surface disposed between said first and second ends;
said walled surface comprising a helical shape of woven monofilaments
comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

48. (previously presented) The stent of claim 47, wherein said blend of bioresorbable, bio-compatible polymers is selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

49. (previously presented) The stent of claim 47, wherein said walled structure has approximately 30 monofilaments.

50. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

51. (currently amended) The stent of claim 47, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi ~~and to~~ 2,000,000 psi.

52. (currently amended) The stent of claim 47, wherein said stent has a compressed first diameter of between approximately 6 mm ~~to~~ and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

53. (currently amended) The stent of claim 47, wherein said woven monofilaments have a crossing angle of between approximately 100 degrees ~~to~~ and 150 degrees in the non-compressed resting state.

54. (previously presented) The stent of claim 46, wherein the stent comprises a substantially tubular shaped device;
said tubular shape device having a first and second ends;
a walled structure disposed between said first and second ends;
said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

55. (previously presented) The stent of claim 54, wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

56. (previously presented) The stent of claim 54, wherein said polymer blend possesses a tensile strength in the range of approximately 8,000 psi to 12,000 psi.

57. (currently amended) The stent of claim 54, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi ~~and to~~ 800,000 psi.

58. (currently amended) The stent of claim 54, wherein said stent has a compressed first diameter of between approximately 6 mm ~~to~~ and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

59. (previously presented) The stent of claim 46, wherein the stent is a urethral stent.

60. (currently amended) The stent of claim 46, wherein the stent comprises a blend of homopolymers in a ratio of between approximately 50:50 ~~to~~ and 70:30.

61. (previously presented) A bioresorbable, self-expanding stent comprising, wherein the stent comprises a substantially tubular shaped device;
said tubular shape device having a first and second ends;
a walled structure disposed between said first and second ends;
said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

62. (previously presented) The stent of claim 61 wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

63. (currently amended) The stent of claim 61 wherein said stent has a compressed first diameter of between approximately 6 millimeter ~~to~~ and 10 millimeter and a second non-compressed diameter of between approximately 12 millimeter and 18 millimeter.

64. (previously presented) The stent of claim 61 wherein the stent is a urethral stent.

65. (currently amended) The stent of claim 61 wherein the stent comprises a blend of homopolymers in a ratio of between approximately 50:50 ~~to~~ and 70:30.

Please add new claims 66-75:

66. (new) The stent of claim 10, wherein said polymers are poly-L-lactide and poly-ε-caprolactone.

67. (new) The stent of claim 66, wherein poly-L-lactide and poly-ε-caprolactone are present at a ratio between approximately 80:20 and 99:1.

68. (new) The stent of claim 67, wherein the ratio is approximately 90:10.

69. (new) The stent of claim 66 wherein the poly-L-lactide has a molecular weight of approximately 450,000 daltons or greater.

70. (new) The stent of claim 69 wherein the poly-L-lactide has a molecular weight of approximately 750,000 daltons or greater.

71. (new) The stent of claim 66 wherein the poly-ε-caprolactone has a molecular weight of approximately 100,000 daltons or greater.

72. (new) The stent of claim 71 wherein the poly-ε-caprolactone has a molecular weight of approximately 200,000 daltons or greater.

73. (new) The stent of claim 62, wherein said polymers are poly-L-lactide and poly-D-L-lactide.

74. (new) The stent of claim 73 wherein the poly-D-L-lactide has a molecular weight of approximately 100,000 daltons or greater.

75. (new) The stent of claim 74 wherein the poly-D-L-lactide has a molecular weight of approximately 500,000 daltons or greater.